Navigation Links
Results From Investigator-Sponsored Trials Presented at SSIEM Conference
Date:9/1/2010

prises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC. Contact:Eugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
2. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
3. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
4. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
5. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
6. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
7. Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)
8. MedClean Technologies Announces Second Quarter Results
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Incorporated,(Nasdaq: VICL ) today announced the receipt ... from AnGes MG, Inc., under a previously announced,collaborative ... Phase 3 metastatic melanoma trial. Through a series ... $15.3 million to date,of the $22.6 million total ...
... vaccine induced neutralizing antibodies against widely divergent ... Baxter International,Inc. (NYSE: BAX ) announced publication ... England Journal of Medicine (NEJM) of data demonstrating ... I/II trial,endpoints for safety and immunogenicity (generating a ...
Cached Medicine Technology:Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... RANCHO CORDOVA, Calif., March 9 ... program announced it helped the 500,000th child since ... almost $100 million in free eyecare and eyewear ... http://www.newscom.com/cgi-bin/prnh/20090309/SF80394 )Sight for Students started as ...
... Usage Trends and Growing Uninsured Population Raise Concerns ... Report from HealthLeaders-InterStudy NASHVILLE, Tenn., March 9 ... market intelligence, reports that through the first three ... health insurers saw on average a 25 percent ...
... with therapy if subjects are willing and motivatedANN ARBOR, Mich., ... raised in an upper-middle class suburb, she felt a deep ... basement where she rode her Big Wheel at age 3 ... 8.As years went by, the home,s empty spaces disappeared, replaced ...
... Nu Skin Presents Findings at Asian Societies of Cosmetic ... a newly identified internal free radical generator, age-related NOX ... (NYSE: NUS ) links the enzyme to ... The research was presented at the 9th Scientific Conference ...
... Philanthropist and Renowned Chef Art Smith Creates Oat-Inspired Menu ... In Times Square today, Quaker announces ... purpose movement powered by Quaker and the human energy ... lives every day with the wholesome goodness of whole-grain ...
... wireless customer relationship management (CRM) experts, today ... and compliance software solution. iComply helps companies ... email for improved compliance with government regulations, ... The software is offered with a Lotus ...
Cached Medicine News:Health News:VSP's Sight for Students Program Helps 500,000th Child 2Health News:VSP's Sight for Students Program Helps 500,000th Child 3Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 2Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 3Health News:Compulsive Hoarding Poses Safety and Psychological Risks 2Health News:Compulsive Hoarding Poses Safety and Psychological Risks 3Health News:Study Links Internal Source of Aging and Skin Damage 2Health News:Study Links Internal Source of Aging and Skin Damage 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 2Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 4Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 5Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 2Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 3
Y shape rotator tip. Shaft angled 7 mm from tip to bend. Round knurled handle with polished finish. Most popular size or model....
1.0 mm long 120 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
Delicate membrane hook/pick with hook on side of instrument for engaging membranes. 20 gauge shaft with balanced titanium handle. Dark finish for reduced glare. Right....
Delicate pick with 90 degree hook tip. 20 gauge shaft with balanced titanium handle. Dark finish for reduced glare....
Medicine Products: